Differential innate immune responses to low or high dose oral SIV challenge in Rhesus macaques

Current HIV Research

Volumn 9, Issue 5, 2011, Pages 276-288

  Durudas, Andre ^a   Chen, Hui Ling ^a   Gasper, Melanie A ^a   Sundaravaradan, Vasudha ^a   Milush, Jeffrey M ^b   Silvestri, Guido ^c   Johnson, Welkin ^d   Giavedoni, Luis D ^e   Sodora, Donald L ^a  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EMORY UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

AIDS; HIV; Innate immune responses; Low dose; Oral transmission; Rhesus macaques; SIV

Indexed keywords

CXCL9 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; INNATE IMMUNITY; NONHUMAN; PROVOCATION TEST; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS IMMUNITY; VIRUS LOAD;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, CD; BLOOD CELLS; CYTOKINES; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; GENOTYPE; IMMUNITY, INNATE; LEUKOCYTES, MONONUCLEAR; LYMPH NODES; MACACA MULATTA; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; UP-REGULATION; VIRAL LOAD;

EID: 80053944260     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016211797635928     Document Type: Article

References (85)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-20.
2. Vaccari M, Poonam P, Franchini G. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev Vaccines 2010; 9: 997-1005.
3. Benmira S, Bhattacharya V, Schmid ML. An Effective HIV Vaccine: A Combination of Humoral and Cellular Immunity? Curr HIV Res 2010; 8: 441-9.
4. Jotwani R, Cutler CW. Multiple dendritic cell (DC) subpopulations in human gingiva and association of mature DCs with CD4+ Tcells in situ. J Dent Res 2003; 82: 736-41.
5. Chou LL, Epstein J, Cassol SA, West DM, He W, Firth JD. Oral mucosal Langerhans' cells as target, effector and vector in HIV infection. J Oral Pathol Med 2000; 29: 394-402.
6. Milush JM, Kosub D, Marthas M, et al. Rapid dissemination of SIV following oral inoculation. AIDS 2004; 18: 2371-80.
7. Zhang Z, Schuler T, Zupancic M, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 1999; 286: 1353-7.
8. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198: 687-93.
9. Kaul R, Pettengell C, Sheth PM, et al. The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. J Reprod Immunol 2008; 77: 32-40.
10. Chakraborty H, Sen PK, Helms RW, et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS 2001; 15: 621-7.
11. Hirbod T, Broliden K. Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women. J Intern Med 2007; 262: 44-58.
12. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000; 74: 5577-86.
13. Chenine AL, Siddappa NB, Kramer VG, et al. Relative transmissibility of an R5 clade C simian-human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes. J Infect Dis 2010; 201: 1155-63.
14. Willumsen JF, Newell ML, Filteau SM, et al. Variation in breastmilk HIV-1 viral load in left and right breasts during the first 3 months of lactation. AIDS 2001; 15: 1896-8.
15. Shepard RN, Schock J, Robertson K, et al. Quantitation of human immunodeficiency virus type 1 RNA in different biological compartments. J Clin Microbiol 2000; 38: 1414-8.
16. Vernazza PL, Gilliam BL, Dyer J, et al. Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 1997; 11: 987-93.
17. Rousseau CM, Nduati RW, Richardson BA, et al. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis 2003; 187: 741-7.
18. Semba RD, Kumwenda N, Hoover DR, et al. Human immunodeficiency virus load in breast milk, mastitis, and motherto- child transmission of human immunodeficiency virus type 1. J Infect Dis 1999; 180: 93-8.
19. O'Byrne P, MacPherson PA. Understanding HIV viral load: implications for counselling. Can J Public Health 2008; 99: 189-91.
20. Li Q, Duan L, Estes J, et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005; 434: 1148-52.
21. Letvin NL, King NW. Immunologic and pathologic manifestations of the infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Acquir Immune Defic Syndr 1990; 3: 1023-40.
22. Hirsch VM, Lifson JD. Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention. Adv Pharmacol 2000; 49: 437-77.
23. Desrosiers RC. The simian immunodeficiency viruses. Annu Rev Immunol 1990; 8: 557-78.
24. Hirsch VM, Johnson PR. Pathogenic diversity of simian immunodeficiency viruses. Virus Res 1994; 32: 183-203.
25. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005; 434: 1093-7.
26. Kosub DA, Durudas A, Lehrman G, et al. Gamma/Delta T cell mRNA levels decrease at mucosal sites and increase at lymphoid sites following an oral SIV infection of macaques. Curr HIV Res 2008; 6: 520-30.
27. Durudas A, Milush JM, Chen H-L, Engram JC, Silvestri G, Sodora DL. Elevated levels of innate immune modulators in lymph nodes and blood are associated with more-rapid disease progression in simian immunodeficiency virus-infected monkeys. J Virol 2009; 83: 12229-40.
28. Milush JM, Stefano-Cole K, Schmidt K, Durudas A, Pandrea I, Sodora DL. Mucosal innate immune response associated with a timely humoral immune response and slower disease progression after oral transmission of simian immunodeficiency virus to rhesus macaques. J Virol 2007; 81: 6175-86.
29. Abel K, Pahar B, Van Rompay KK, et al. Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses. J Virol 2006; 80: 6357-67.
30. Scarlatti G. Mother-to-child transmission of HIV-1: advances and controversies of the twentieth centuries. AIDS Rev 2004; 6: 67-78.
31. Mofenson LM. Interaction between timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions. Acta Paediatr Suppl 1997; 421: 1-9.
32. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000; 283: 1167-74.
33. Fawzi W, Msamanga G, Spiegelman D, et al. Transmission of HIV-1 through breastfeeding among women in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr 2002; 31: 331-8.
34. Bratt GA, Berglund T, Glantzberg BL, Albert J, Sandström E. Two cases of oral-to-genital HIV-1 transmission. Int J STD AIDS 1997; 8: 522-5.
35. Rothenberg RB, Scarlett M, del Rio C, Reznik D, O'Daniels C. Oral transmission of HIV. AIDS 1998; 12: 2095-105.
36. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125: 257-64.
37. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150: 306-11.
38. Ruprecht RM, Baba TW, Liska V, et al. Oral SIV, SHIV, and HIV type 1 infection. AIDS Res Hum Retroviruses 1998; 14 Suppl 1: S97-103.
39. Baba TW, Koch J, Mittler ES, et al. Mucosal infection of neonatal rhesus monkeys with cell-free SIV. AIDS Res Hum Retroviruses 1994; 10: 351-7.
40. Baba TW, Trichel AM, An L, et al. Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV. Science 1996; 272: 1486-9.
41. Ferrantelli F, Rasmussen RA, Buckley KA, et al. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti- HIV monoclonal antibodies. J Infect Dis 2004; 189: 2167-73.
42. Van Rompay KK, Greenier JL, Cole KS, et al. Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol 2003; 77: 179-90.
43. Van Rompay KK, Abel K, Lawson JR, et al. Attenuated poxvirusbased simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr 2005; 38: 124-34.
44. Hansen SG, Vieville C, Whizin N, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15: 293-9.
45. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105: 7552-7.
46. Salazar-Gonzalez JF, Bailes E, Pham KT, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008; 82: 3952-70.
47. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009; 206: 1253-72.
48. Stone M, Keele BF, Ma ZM, et al. A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol 2010; 84: 7083-95.
49. Miller C, Li Q, Abel K, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005; 79: 9217-27.
50. Haaland R, Hawkins P, Salazar-Gonzalez J, et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 2009; 5: e1000274.
51. Keele BF, Li H, Learn GH, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009; 206: 1117-34.
52. Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9: 118-29.
53. Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual infectivity of HIV-1: a systematic review and metaanalysis. Lancet Infect Dis 2008; 8: 553-63.
54. Bar KJ, Li H, Chamberland A, Tremblay C, Routy JP, Grayson T, et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 2010; 84: 6241-7.
55. Li H, Bar KJ, Wang S, et al. High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog 2010; 6: e1000890.
56. Greenier JL, Miller CJ, Lu D, et al. Route of simian immunodeficiency virus inoculation determines the complexity but not the identity of viral variant populations that infect rhesus macaques. J Virol 2001; 75: 3753-65.
57. Marthas ML, Lu D, Penedo MC, Hendrickx AG, Miller CJ. Titration of an SIVmac251 stock by vaginal inoculation of Indian and Chinese origin rhesus macaques: transmission efficiency, viral loads, and antibody responses. AIDS Res Hum Retroviruses 2001; 17: 1455-66.
58. Engram J, Dunham R, Makedonas G, et al. Vaccine-induced, Simian Immunodeficiency Virus-specific CD8+ T cells reduce virus replication but do not protect from Simian Immunodeficiency Virus disease progression. J Immunol 2009; 183: 706-17.
59. Marx PA, Spira AI, Gettie A, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996; 2: 1084-9.
60. Pachl C, Todd JA, Kern DG, et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 446-54.
61. Leutenegger CM, Higgins J, Matthews TB, et al. Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA. AIDS Res Hum Retroviruses 2001; 17: 243-51.
62. Abel K, Alegria-Hartman MJ, Rothaeusler K, Marthas M, Miller CJ. The relationship between simian immunodeficiency virus RNA levels and the mRNA levels of alpha/beta interferons (IFNalpha/ beta) and IFN-alpha/beta-inducible Mx in lymphoid tissues of rhesus macaques during acute and chronic infection. J Virol 2002; 76: 8433-45.
63. Abel K, Compton L, Rourke T, et al. Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. J Virol 2003; 77: 3099-118.
64. Sodora DL, Lee F, Dailey PJ, Marx PA. A genetic and viral load analysis of the simian immunodeficiency virus during the acute phase in macaques inoculated by the vaginal route. AIDS Res Hum Retroviruses 1998; 14: 171-81.
65. Kirmaier A, Wu F, Newman RM, et al. TRIM5 suppresses crossspecies transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol 2010; 8: e1000462.
66. Almond N, Jenkins A, Heath AB, Kitchin P. Sequence variation in the env gene of simian immunodeficiency virus recovered from immunized macaques is predominantly in the V1 region. J Gen Virol 1993; 74 (Pt 5): 865-71.
67. Overbaugh J, Rudensey LM, Papenhausen MD, Benveniste RE, Morton WR. Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS. J Virol 1991; 65: 7025-31.
68. Tao B, Fultz PN. Molecular and biological analyses of quasispecies during evolution of a virulent simian immunodeficiency virus, SIVsmmPBj14. J Virol 1995; 69: 2031-7.
69. Sagar M, Lavreys L, Baeten JM, et al. Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol 2003; 77: 12921-6.
70. Benveniste O, Vaslin B, Le Grand R, et al. Comparative interleukin (IL-2)/interferon IFN-gamma and IL-4/IL-10 responses during acute infection of macaques inoculated with attenuated neftruncated or pathogenic SICmac251 virus. Proc Natl Acad Sci U S A 1996; 93: 3658-63.
71. Abel K, Rocke DM, Chohan B, Fritts L, Miller CJ. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol 2005; 79: 12164-72.
72. Benveniste O, Vaslin B, Le Grand R, et al. Interleukin 1 beta, interleukin 6, tumor necrosis factor alpha, and interleukin 10 responses in peripheral blood mononuclear cells of cynomolgus macaques during acute infection with SIVmac251. AIDS Res Hum Retroviruses 1996; 12: 241-50.
73. Cheret A, Le Grand R, Caufour P, et al. Cytokine mRNA expression in mononuclear cells from different tissues during acute SIVmac251 infection of macaques. AIDS Res Hum Retroviruses 1996; 12: 1263-72.
74. Liu J, Keele BF, Li H, et al. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol 2010; 84: 10406-12.
75. Chakrabarti A, Jha BK, Silverman RH. New insights into the role of RNase L in innate immunity. J Interferon Cytokine Res 2011; 31: 49-57.
76. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011; 89: 207-15.
77. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997; 61: 246-57.
78. Loetscher M, Loetscher P, Brass N, Meese E, Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 1998; 28: 3696-705.
79. Loetscher M, Gerber B, Loetscher P, et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184: 963-9.
80. Kim CH, Rott L, Kunkel EJ, et al. Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest 2001; 108: 1331-9.
81. Yamamoto J, Adachi Y, Onoue Y, et al. Differential expression of the chemokine receptors by the Th1- and Th2-type effector populations within circulating CD4+ T cells. J Leukoc Biol 2000; 68: 568-74.
82. Witt PL, Spear GT, Helgeson DO, Lindstrom MJ, Smalley RV, Borden EC. Basal and interferon-induced 2',5'-oligoadenylate synthetase in human monocytes, lymphocytes, and peritoneal macrophages. J Interferon Res 1990; 10: 393-402.
83. Delwart EL, Sheppard HW, Walker BD, Goudsmit J, Mullins JI. Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol 1994; 68: 6672-83.
84. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261: 1179-81.
85. Abrahams MR, Anderson JA, Giorgi EE, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol 2009; 83: 3556-67.